Drug intelligence / Profile preview

eribulin + pembrolizumab

Development stage: Unknown
Lead developer: Eisai
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This combination involves **eribulin**, a synthetic macrocyclic ketone analogue of the marine natural product halichondrin B, which acts as a microtubule inhibitor, and **pembrolizumab**, a monoclonal antibody that targets the programmed death receptor-1 (PD-1), enhancing the body's immune response against cancer cells. The combination is explored for its potential synergistic effects in modulating the tumor-immune microenvironment.

Brand names: Halaven + Keytruda
Other names: eribulin and pembrolizumabpembrolizumab and eribulinKeytruda + Halaven

Targets

PDCD1 (Programmed cell death protein 1 receptor)Microtubule

Beyond the preview

Go deeper on eribulin + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eribulin + pembrolizumab.

Explore the full profile